- Tucked in its Q3 earnings release on Monday afternoon, Surrozen Inc (NASDAQ:SRZN) voluntarily paused enrollment in the single ascending dose (SAD) portion of its Phase 1 trial evaluating SZN-1326 in healthy volunteers following the observation of treatment-related adverse events.
- SZN-1326 is a Wnt mimetic bi-specific antibody that selectively activates the Wnt pathway and is in development for ulcerative colitis.
- Several subjects experienced asymptomatic liver transaminase elevations (elevated liver enzymes), including three subjects with grade 3 ALT and AST elevations.
- Related: Surrozen Inks Strategic Partnership With Boehringer Ingelheim For Retinal Disease Candidate.
- Elevated levels of either of these enzymes are potential indicators of liver damage or liver disease.
- There were no corresponding increases in total bilirubin nor any changes in liver function markers such as coagulation markers or albumin.
- No other clinically significant laboratory abnormalities were observed, and the transaminase elevations resolved spontaneously in all subjects.
- No serious adverse events were observed during the study.
- Price Action: SRZN shares closed 30.2% lower at $1.25 on Tuesday.
Meta Platforms To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday
BMO Capital boosted the price target for Equity Residential (NYSE: EQR) from $60 to $64. BMO Capital analyst John Kim upgraded the stock from Underperform to Market Perform. Equity Residential shares rose 0.7% to $63.56 in pre-market trading.
